In-depth research guides covering peptides, compounds, and laboratory supplies. For research use only.
Multiple peptides have been studied in the context of anxiety, stress resilience, and neuroinflammation. This guide covers the research on Selank, Semax, DSIP, KPV, and Pinealon — their mechanisms of action, published study data, and what distinguishes each compound.
Peptide half-life is one of the most important pharmacokinetic parameters in research design, yet it’s frequently misunderstood. This guide explains what half-life means for peptides, what factors influence it, and how to interpret half-life data across common research compounds.
Semaglutide and cagrilintide represent two distinct pharmacological approaches to weight management research. This comparison covers mechanism of action, clinical trial data, the CagriSema combination, and what the research suggests about their complementary effects.
Joint pain is one of the most studied research areas for peptides. BPC-157 regenerates tendons. TB-500 rebuilds tissue. GHK-Cu synthesizes collagen. KPV suppresses inflammation. This article covers what the research actually shows for each compound.
Two different peptides. Two different receptor systems. One combined effect that exceeds what either can do alone. This is why the CJC-1295 No DAC and Ipamorelin blend has become one of the most studied growth hormone secretagogue combinations in research.
Semaglutide changed obesity research. Retatrutide may have changed it again. Here is what the clinical data actually shows when you put a single GLP-1 agonist head-to-head against a triple receptor agonist — and why the difference matters.
A research comparison of tirzepatide (dual GIP/GLP-1 agonist) and retatrutide (triple GIP/GLP-1/glucagon agonist) — covering mechanisms, clinical trial efficacy data, metabolic effects, side effect profiles, and what the evidence suggests about each compound’s research potential.
A beginner-friendly guide to how peptides work at a molecular level — covering receptor binding, signal transduction, major peptide categories, and bioavailability considerations for researchers.
A concise overview of retatrutide (LY3437943), the first triple GLP-1/GIP/glucagon receptor agonist to reach Phase 3 trials — covering its mechanism, key clinical data, and why it has captured the attention of metabolic researchers.
Cardiogen is a tetrapeptide bioregulator developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation. This guide covers its cardiac tissue specificity, mechanism of action in cardiomyocyte gene regulation, research findings on cardioprotection and myocardial repair, dosing protocols in preclinical studies, and comparison to other cardiac-relevant peptides.
